Mylan Wins Motion for Temporary Restraining Order Against Apotex for Authorized Generic of Paxil® CR

     Mylan Wins Motion for Temporary Restraining Order Against Apotex for
                       Authorized Generic of Paxil® CR

District Court Judge Orders Apotex to Immediately Recall the Authorized
Generic from its Direct Customers and to Stop Selling and Supplying the
Product

PR Newswire

PITTSBURGH, July 23, 2014

PITTSBURGH, July 23, 2014 /PRNewswire/ -- Mylan Inc. (Nasdaq: MYL) today
announced that the U.S. District Court for the District of New Jersey granted
its motion for a temporary restraining order against Apotex Inc. and Apotex
Corporation in litigation relating to Paroxetine CR, the authorized generic of
GlaxoSmithKline's Paxil^® CR. The District Court ordered Apotex to immediately
discontinue all sales and supply of Paroxetine CR. Mylan previously obtained
an order enjoining GlaxoSmithKline from supplying Paroxetine CR to Apotex.

Mylan

In addition, the District Court ordered Apotex to immediately recall all
product from its direct customers that was shipped since the injunction was
entered on July 16, 2014.

Mylan has an exclusive license to an Orange Book patent pertaining to Paxil CR
which expires in July 2016, with pediatric exclusivity extending until Jan.
19, 2017. Mylan further believes that it is the only company to have filed an
abbreviated new drug application for generic Paxil CR that contains a
paragraph IV certification.

Mylan is a global pharmaceutical company committed to setting new standards in
health care. Working together around the world to provide 7 billion people
access to high quality medicine, we innovate to satisfy unmet needs; make
reliability and service excellence a habit; do what's right, not what's easy;
and impact the future through passionate global leadership. We offer a growing
portfolio of more than 1,300 generic pharmaceuticals and several brand
medications. In addition, we offer a wide range of antiretroviral therapies,
upon which approximately 40% of HIV/AIDS patients in developing countries
depend. We also operate one of the largest active pharmaceutical ingredient
manufacturers and currently market products in approximately 140 countries and
territories. Our workforce of more than 20,000 people is dedicated to
improving the customer experience and increasing pharmaceutical access to
consumers around the world. But don't take our word for it. See for yourself.
See inside. mylan.com

Logo - http://photos.prnewswire.com/prnh/20140423/77793

SOURCE Mylan Inc.

Website: http://www.mylan.com
Contact: Nina Devlin (Media) 724.514.1968 or Kris King (Investors)
724.514.1813
 
Press spacebar to pause and continue. Press esc to stop.